1. Home
  2. TENX vs PFX Comparison

TENX vs PFX Comparison

Compare TENX & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.72

Market Cap

74.1M

Sector

Health Care

ML Signal

N/A

PFX

PhenixFIN Corporation

N/A

Current Price

$41.00

Market Cap

86.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
PFX
Founded
1967
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
74.1M
86.7M
IPO Year
2001
2010

Fundamental Metrics

Financial Performance
Metric
TENX
PFX
Price
$1.72
$41.00
Analyst Decision
Buy
Analyst Count
10
0
Target Price
★ $9.63
N/A
AVG Volume (30 Days)
★ 2.0M
1.1K
Earning Date
11-11-2026
12-11-2026
Dividend Yield
N/A
★ 3.66%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.30
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$130.33
Revenue Growth
N/A
★ N/A
52 Week Low
$1.31
$38.30
52 Week High
$19.40
$56.48

Technical Indicators

Market Signals
Indicator
TENX
PFX
Relative Strength Index (RSI) 42.67 36.43
Support Level $1.34 $38.82
Resistance Level $2.00 $42.54
Average True Range (ATR) 0.12 0.17
MACD 0.09 -0.40
Stochastic Oscillator 70.91 28.88

Price Performance

Historical Comparison
TENX
PFX

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

Share on Social Networks: